743 related articles for article (PubMed ID: 14528085)
1. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
[TBL] [Abstract][Full Text] [Related]
2. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
[TBL] [Abstract][Full Text] [Related]
3. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
[TBL] [Abstract][Full Text] [Related]
4. Intermittent hormone therapy in nonmetastatic prostate cancer.
Opfermann KJ; Lai Z; Essenmacher L; Bolton S; Ager J; Forman JD
Clin Genitourin Cancer; 2006 Sep; 5(2):138-43. PubMed ID: 17026802
[TBL] [Abstract][Full Text] [Related]
5. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
7. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
Pether M; Goldenberg SL; Bhagirath K; Gleave M
Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
9. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
[TBL] [Abstract][Full Text] [Related]
10. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
11. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
12. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
13. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
[TBL] [Abstract][Full Text] [Related]
14. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.
Beekman K; Morris M; Slovin S; Heller G; Wilton A; Bianco F; Scardino PT; Scher HI
Urology; 2005 May; 65(5):947-52. PubMed ID: 15882729
[TBL] [Abstract][Full Text] [Related]
16. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
17. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
19. Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer.
Cury FL; Souhami L; Rajan R; Tanguay S; Gagnon B; Duclos M; Shenouda G; Faria SL; David M; Freeman CR
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):842-8. PubMed ID: 16289909
[TBL] [Abstract][Full Text] [Related]
20. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
